TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27565717

Group type: EXPERIMENTAL
Intervention: SMS reminder messages (monthly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 48
Study: 25438908

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 13032

Group type: COMPARATOR
Intervention: No Anemia
Number of subjects: 13032
Study: 23409591

Group type: EXPERIMENTAL
Intervention: Prehabilitation exercise intervention (3 times per week for 8 weeks prior to surgery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual preoperative care prescribed by the physician (Control)
Number of subjects: 18
Study: 20975053

Group type: EXPERIMENTAL
Intervention: 1.5 μg/min human αCGRP infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan subcutaneous injection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 18
Study: 18550577

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 627

Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 627
Study: 16507381

Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension
Number of subjects: 965

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate potassium, cefprozil, azithromycin, or generic amoxicillin
Number of subjects: 965
Study: 11986112

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Composite International Diagnostic Interview, Short Form (CIDI-SF)
Number of subjects: 298

Group type: COMPARATOR
Intervention: N/A (control group)
Number of subjects: 298
Study: 11127759

Group type: EXPERIMENTAL
Intervention: Esterified estrogens (0.3 mg, 0.625 mg, or 1.25 mg)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 8761904

Group type: EXPERIMENTAL
Intervention: Helical computed tomography (CT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Digital subtraction angiography (control)
Number of subjects: 50
Study: 1552456

Group type: EXPERIMENTAL
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2‐stage coronally‐positioned flap (CPF)
Number of subjects: 8
Study: 3698460

Group type: EXPERIMENTAL
Intervention: 1.5 mg lorazepam
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 3.0 mg lorazepam
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29277822

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) and cyclophosphamide (150-250 mg/m2) added to a combination of gemcitabine, fluorouracil, leucovorin, irinotecan and a platinum analogue.
Number of subjects: 9
Study: 24055782

Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 100% of fluid losses (0% hypohydrated)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 33% of fluid losses (-2% hypohydrated)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reinfused with saline to replace 0% of fluid losses (-3% hypohydrated)
Number of subjects: 10
Study: 23760808

Group type: EXPERIMENTAL
Intervention: Lidocaine local analgesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: No lidocaine local analgesia (Control)
Number of subjects: 80
Study: 20053142

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 64
Study: 19134276

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cells (BM‐MNCs) transplantation
Number of subjects: 258

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 258
Study: 16140397

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide booster
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 74
Study: 12499347

Group type: EXPERIMENTAL
Intervention: Iron supplementation (ferrous sulfate 60 mg Fe once daily for 8 weeks)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 10577432

Group type: EXPERIMENTAL
Intervention: Ramped Bruce protocol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bruce protocol
Number of subjects: 23
Study: 7555975

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, single doses of 2-24 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, daily doses of 2-10 mg for 5 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl, daily doses of 6 or 12 mg for 14 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) HCl
Number of subjects: 58
Study: 1940122

Group type: EXPERIMENTAL
Intervention: Vigabatrin (40 to 80 mg/kg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vigabatrin (higher than 100 mg/kg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vigabatrin (monotherapy)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vigabatrin (dose reduction due to hyperkinesia)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 66
Study: 7453240

Group type: EXPERIMENTAL
Intervention: Modified intra-aortic balloon catheter (central-lumen balloon)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard intra-aortic balloon catheter (control group)
Number of subjects: 18
Study: 30135024

Group type: EXPERIMENTAL
Intervention: VMAT + SWO
Number of subjects: 10

Group type: COMPARATOR
Intervention: cVMAT
Number of subjects: 10

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 10
Study: 27888542

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam (4-hour infusion)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam (30-minute infusion)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam
Number of subjects: 367

Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) piperacillin/tazobactam (post hoc analysis)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Non-extended infusion (NEI) piperacillin/tazobactam (post hoc analysis)
Number of subjects: 367
Study: 26353825

Group type: EXPERIMENTAL
Intervention: VIPP-V (Video-feedback Intervention to promote Positive Parenting) in combination with care-as-usual
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 100
Study: 23531117

Group type: EXPERIMENTAL
Intervention: 0.25 mg drospirenone/0.5 mg 17β-estradiol (DRSP/E2)
Number of subjects: 662

Group type: COMPARATOR
Intervention: 0.5 mg norethisterone acetate (NETA)/1.0 mg E2
Number of subjects: 662
Study: 21505096

Group type: EXPERIMENTAL
Intervention: C.E.R.A. 1.2 μg/kg Q4W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alfa QW/Q2W
Number of subjects: 0
Study: 19767815

Group type: EXPERIMENTAL
Intervention: 0% glucose solution
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2% glucose solution
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10% glucose solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypertonic carbohydrate-electrolyte solutions
Number of subjects: 9
Study: 18204744

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized grass/rye mix extract (300 IR/daily)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized grass/rye mix extract
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15274236

Group type: EXPERIMENTAL
Intervention: Flat tibial component with retention of the posterior cruciate ligament
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concave tibial component with retention of the posterior cruciate ligament
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concave tibial component with resection of the posterior cruciate ligament
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posterior-stabilized tibial component with resection of the posterior cruciate ligament
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (17 controls)
Number of subjects: 20
Study: 11704469

Group type: EXPERIMENTAL
Intervention: Educational intervention (nutrition education) for premenopausal women (n = 174)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group (n = 103)
Number of subjects: 277
Study: 9744123

Group type: EXPERIMENTAL
Intervention: 4-part, individually tailored smoking cessation program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 8545714

Group type: EXPERIMENTAL
Intervention: Allograft plus demineralized bone matrix
Number of subjects: 77

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 77
Study: 2614056

Group type: EXPERIMENTAL
Intervention: Novel closed needle-sampling system (Lab-Site, Migada Ltd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stopcock system
Number of subjects: 0
Study: 305734

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) and pethidine as necessary
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular pethidine (30 mg) alone
Number of subjects: 40
Study: 31863561

Group type: EXPERIMENTAL
Intervention: Intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31779711

Group type: EXPERIMENTAL
Intervention: Colistin plus levofloxacin (4.5 million unit loading dose followed by 3 million units every 8 h, levofloxacin 500 mg every 12 h)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Meropenem plus levofloxacin (2 g every 8 h, levofloxacin 500 mg every 12 h)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Colistin plus levofloxacin
Number of subjects: 232

Group type: COMPARATOR
Intervention: Meropenem plus levofloxacin
Number of subjects: 232
Study: 28390688

Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 152

Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 152
Study: 26414481

Group type: EXPERIMENTAL
Intervention: Increased SNAP benefits (13.6% increase of the maximum allotment, equivalent to $24 to $144 for one-to-eight person households)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased SNAP benefits (13.6% increase of the maximum allotment)
Number of subjects: 0
Study: 25270176

Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program (2 interactive seminar sessions of 2.5 hours each)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Physician Asthma Care Education program
Number of subjects: 870
Study: 22795579

Group type: EXPERIMENTAL
Intervention: Vulvectomy and inguinofemoral lymphadenectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy, age-matched women)
Number of subjects: 28
Study: 19318667

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg; n = 336)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg; n = 339)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Atropine and Glycopyrrolate
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo (2 mL of normal saline solution; n = 325)
Number of subjects: 1000
Study: 17697245

Group type: EXPERIMENTAL
Intervention: Thermafil system
Number of subjects: 45

Group type: COMPARATOR
Intervention: System B
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 45
Study: 15014015

Group type: EXPERIMENTAL
Intervention: Temozolomide (TEM) administered orally daily on days 1-5 and BCNU administered intravenously either on day 1 before TEM (Seq B‐‐>T) or day 5 after TEM (Seq T‐‐>B).
Number of subjects: 63

Group type: COMPARATOR
Intervention: Seq T‐‐>B (BCNU on day 5 after TEM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Seq B‐‐>T (BCNU on day 1 before TEM)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: AGAT activity in PBMCs
Number of subjects: 63
Study: 11200353

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced moving-table MR angiography
Number of subjects: 13
Study: 10450426

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 122
Study: 7853071

Group type: EXPERIMENTAL
Intervention: Ethics education program (pilot program in 1988 and full program from 1989 to 1991)
Number of subjects: 152
Study: 2755859

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine (MS Contin, Purdue Frederick Co.)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Short-acting analgesia
Number of subjects: 83
Study: 4837057

Group type: EXPERIMENTAL
Intervention: Physical training (3 months, 3 sessions per week, cycling on an ergometer bicycle)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Reference group (no physical training)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 63
Study: 31479790

Group type: EXPERIMENTAL
Intervention: Subdural drain (SDD)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220
Study: 28492195

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide-60% oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triclofos sodium (70 mg/kg body weight)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both nitrous oxide-oxygen and triclofos sodium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral route of administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhalation route of administration
Number of subjects: 60
Study: 26147295

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 15102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15102
Study: 23273434

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m² biweekly on days 1, 4, 8, and 11 of a 21-day cycle (arm A)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bortezomib 1.6 mg/m² weekly on days 1, 8, 15, and 22 of a 35-day cycle (arm B)
Number of subjects: 87
Study: 21641773

Group type: EXPERIMENTAL
Intervention: Nonnumbered questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numbered questionnaire
Number of subjects: 0
Study: 18820852

Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with keto-amino acids (100 mg/kg BW per day)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 16855170

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha monoclonal antibody infliximab
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (14 patients on other anti-TNF therapies and 20 negative controls)
Number of subjects: 7
Study: 15733432

Group type: EXPERIMENTAL
Intervention: Array IOL
Number of subjects: 255

Group type: COMPARATOR
Intervention: Monofocal Hydroview IOL
Number of subjects: 255
Study: 11286539

Group type: COMPARATOR
Intervention: Four 5-day IL-2 cycles every 8 weeks (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Four cycles of longer duration (mean 7.7-days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Increased frequency of 5-day cycles (every 4.1 weeks on average)
Number of subjects: 22
Study: 9029744

Group type: EXPERIMENTAL
Intervention: 12.5-cm2 once-a-week adhesive patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25-cm2 once-a-week adhesive patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-cm2 twice-a-week Estraderm patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20-cm2 twice-a-week Estraderm patch
Number of subjects: 0
Study: 7973004

Group type: EXPERIMENTAL
Intervention: Vitamin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineral components
Number of subjects: 0
Study: 3263890

Group type: EXPERIMENTAL
Intervention: 40 mg of prednisone given daily for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30684954

Group type: EXPERIMENTAL
Intervention: Positive attitude towards conducting research
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Barriers encountered during research
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Insufficient research allotted time
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Insufficient financial support
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lack of financial incentives
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lack of statistical support
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Physicians designation and board certificate
Number of subjects: 200
Study: 28502831

Group type: EXPERIMENTAL
Intervention: Sucralose (333.3 mg, encapsulated, 3x/day at mealtimes)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 47
Study: 25567656

Group type: EXPERIMENTAL
Intervention: Limited fluid resuscitation combined with blood pressure-controlling drugs
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional fluid resuscitation (conventional group)
Number of subjects: 51
Study: 22923230

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100% N(2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10% CO(2) + 90% N(2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resumption of breathing after apnoea
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inspiratory-capacity apnoea with various gases
Number of subjects: 11
Study: 21443994

Group type: EXPERIMENTAL
Intervention: Latino Dietary Behaviors Questionnaire (LDBQ) intervention group
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study: 19224793

Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 60
Study: 16732710

Group type: EXPERIMENTAL
Intervention: Daily corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent corticosteroids
Number of subjects: 0
Study: 12911327

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Celiprolol (beta-blocker)
Number of subjects: 98
Study: 10973679

Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.8‐4.2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Warfarin and Aspirin)
Number of subjects: 40
Study: 9069728

Group type: EXPERIMENTAL
Intervention: X-rays initiated at triage
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard procedure (no X-rays initiated at triage)
Number of subjects: 175
Study: 8438096

Group type: EXPERIMENTAL
Intervention: Oral salbutamol controlled release (SCR) 8 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3300762

Group type: EXPERIMENTAL
Intervention: Total or subtotal nodal irradiation
Number of subjects: 142
Study: 29890985

Group type: EXPERIMENTAL
Intervention: Real Neuromuscular Taping (NMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 40
Study: 28359212

Group type: EXPERIMENTAL
Intervention: pACP intervention (three 60-minute sessions scheduled one week apart)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: pACP intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Active control (developmental history, safety tips, nutrition and exercise education)
Number of subjects: 105
Study: 26242401

Group type: EXPERIMENTAL
Intervention: Interactive VRET plus conventional analgesics
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Passive VRET with conventional analgesics
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional analgesics alone
Number of subjects: 25
Study: 24503402

Group type: EXPERIMENTAL
Intervention: Fondaparinux with tirofiban
Number of subjects: 389

Group type: COMPARATOR
Intervention: Enoxaparin with tirofiban
Number of subjects: 389
Study: 21120152

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17846044

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 17032093

Group type: EXPERIMENTAL
Intervention: Writing about personal benefits resulting from the transgression
Number of subjects: 304

Group type: COMPARATOR
Intervention: Writing about traumatic features of the transgression
Number of subjects: 304

Group type: COMPARATOR
Intervention: Writing about a control topic unrelated to the transgression
Number of subjects: 304
Study: 12743142

Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiotherapy (WP RT) + Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PO RT) + Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Whole-pelvic radiotherapy (WP RT) + Adjuvant hormonal therapy (AHT)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PO RT) + Adjuvant hormonal therapy (AHT)
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Neoadjuvant combined androgen suppression (NCHT)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Adjuvant hormonal therapy (AHT)
Number of subjects: 1323

Group type: COMPARATOR
Intervention: All four arms (WP RT + NCHT, PO RT + NCHT, WP RT + AHT, PO RT + AHT)
Number of subjects: 1323
Study: 10781267

Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (free-floating)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (restrained)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laryngoscope-guided tracheal intubation (poolside)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (poolside)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (free-floating)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (restrained)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (poolside)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (free-floating)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (restrained)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (poolside)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (free-floating)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (restrained)
Number of subjects: 4